Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma of the Colon

Trial Profile

A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma of the Colon

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colon cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Results of a genome-wide association study in 2 colon cancer clinical trials (N0147 and C-08) identifying genetic variants associated with overall survival, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 20 Jan 2018 Results from patients receiving adjuvant FOLFOX in MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials (n=7230) presented at the 2018 Gastrointestinal Cancers Symposium
    • 25 Jan 2016 Results of pooled analysis of five studies (C-07, C-08, N0147, MOSAIC and XELOXA) published in the Journal of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top